TIBET PHARMA(600211.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
TIBET PHARMA
600211.SH
Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu capsules, and epilepsy flat film; and recombinant human brain natriuretic peptide for injection. It also provides isosorbide mononitrate sustained-release tablets; and oxygen rhodiola rosea moisturizing essence, secret recipe fragrance powder packet, rhodiola rosea, and Yuan Yang rhodiola rosea moisturizing essence products.
346.11 B
600211.SHMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
B
Health Care DistributorsIndustry
Industry Ranking3/23
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE24.18%A
    • Profit Margin32.32%A
    • Gross Margin92.90%A
  • Growth ScoreC
    • Revenue YoY6.34%C
    • Net Profit YoY-4.00%C
    • Total Assets YoY22.40%A
    • Net Assets YoY2.21%C
  • Cash ScoreC
    • Cash Flow Margin111.48%C
    • OCF YoY6.34%C
  • Operating ScoreC
    • Turnover0.52C
  • Debt ScoreB
    • Gearing Ratio33.86%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Ruizheng Gene completed a $75 million Series A financing, initiating a comprehensive strategic partnership with TIBET PHARMA and CMS

    Zhitong·
    SH
    600211
    -1.01%
    HK
    00867
    -1.41%
    Zhitong·
    SH
    600211
    -1.01%
    HK
    00867
    -1.41%

    Innovative drug concept stocks continue to decline, BrightGene falls over 8%

    Zhitong·
    SH
    601089
    -0.67%
    SH
    688166
    -2.38%
    SH
    600211
    -1.01%
    Zhitong·
    SH
    601089
    -0.67%
    SH
    688166
    -2.38%
    SH
    600211
    -1.01%

    TIBET PHARMA provides a guarantee of 160 million for its subsidiary, with overall risks being controllable

    Zhitong·
    SH
    600211
    -1.01%
    Zhitong·
    SH
    600211
    -1.01%

    TIBET PHARMA released its semi-annual performance report, with a net profit attributable to the parent company of 567 million yuan, a year-on-year decrease of 8.96%

    Zhitong·
    SH
    600211
    -1.01%
    Zhitong·
    SH
    600211
    -1.01%

    TIBET PHARMA released its first-quarter performance, with a net profit attributable to the parent company of 269 million yuan, a year-on-year decrease of 13.95%

    Zhitong·
    SH
    600211
    -1.01%
    Zhitong·
    SH
    600211
    -1.01%
    © 2026 Longbridge｜Disclaimer